UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patients

Journal of viral hepatitis, 2017-10, Vol.24 (10), p.895-899

2017

Volltextzugriff (PDF)

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

The lancet HIV, 2018-01, Vol.5 (1), p.e23-e34

2018

Volltextzugriff (PDF)

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Mucosal immunology, 2022-05, Vol.15 (5), p.799-808

2022

Volltextzugriff (PDF)

Super‐resolution Imaging of Amyloid Structures over Extended Times by Using Transient Binding of Single Thioflavin T Molecules

Chembiochem : a European journal of chemical biology, 2018-09, Vol.19 (18), p.1944-1948

2018

Volltextzugriff (PDF)

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

Journal of hepatology, 2017, Vol.66 (1), p.S85-S85

2017

Volltextzugriff (PDF)

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Clinical infectious diseases, 2022-01, Vol.74 (2), p.218-226

2022

Volltextzugriff (PDF)

Prompt engineering to increase GPT3.5’s performance on the Plastic Surgery In-Service Exams

Journal of plastic, reconstructive & aesthetic surgery, 2024-11, Vol.98, p.158-160

2024

Volltextzugriff (PDF)

P0776 : Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients

Journal of hepatology, 2015-04, Vol.62, p.S621-S621

2015

Volltextzugriff (PDF)

Normscan: open-source Python software to create average models from CT scans

International journal for computer assisted radiology and surgery, 2024-05

2024

Volltextzugriff (PDF)

22. Enhancing The Accuracy Of Planned Surgery With Computer Controlled Osteotomies

Plastic and reconstructive surgery. Global open, 2024-05, Vol.12 (Suppl), p.16-16

2024

Volltextzugriff (PDF)

Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium

Journal of molecular biology, 2021-04, Vol.433 (8), p.166878-166878, Article 166878

2021

Volltextzugriff (PDF)

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

Journal of hepatology, 2016, Vol.64 (2), p.S771-S771

2016

Volltextzugriff (PDF)

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

Journal of hepatology, 2016, Vol.64 (2), p.S139-S140

2016

Volltextzugriff (PDF)

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Journal of hepatology, 2015-04, Vol.62, p.S270-S270

2015

Volltextzugriff (PDF)

O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY

Journal of hepatology, 2014-04, Vol.60 (1), p.S26-S26

2014

Volltextzugriff (PDF)

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Journal of hepatology, 2014-04, Vol.60 (1), p.S46-S46

2014

Volltextzugriff (PDF)

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

Annals of internal medicine, 2016-11, Vol.165 (9), p.625

2016

Volltextzugriff (PDF)

The Infectious Diseases Physician in the Future of Healthcare: Not Only About Antibiotic Prescribing

Clinical infectious diseases, 2015-03, Vol.60 (5), p.773-776

Nahass, Ronald G.

2015

Volltextzugriff (PDF)

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

The New England journal of medicine, 2014-05, Vol.370 (21), p.1983-1992

2014

Volltextzugriff (PDF)

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

Journal of Virus Eradication, 2017-08, Vol.3, p.8

2017

Volltextzugriff (PDF)

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

The Lancet (British edition), 2013-03, Vol.381 (9868), p.735-743

2013

Volltextzugriff (PDF)

The Value of Infectious Diseases Specialists: Non–Patient Care Activities

Clinical infectious diseases, 2008-10, Vol.47 (8), p.1051-1063

2008

Volltextzugriff (PDF)

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

PLoS medicine, 2015-03, Vol.12 (3), p.e1001809

2015

Volltextzugriff (PDF)

Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study

The Journal of infectious diseases, 2008-04, Vol.197 (8), p.1133-1144

2008

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(127)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment‐naïve, noncirrhotic HCV genotype 3‐infected patients

Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection

Super‐resolution Imaging of Amyloid Structures over Extended Times by Using Transient Binding of Single Thioflavin T Molecules

Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE)

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Prompt engineering to increase GPT3.5’s performance on the Plastic Surgery In-Service Exams

P0776 : Efficacy of 12 or 18 weeks of grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients

Normscan: open-source Python software to create average models from CT scans

22. Enhancing The Accuracy Of Planned Surgery With Computer Controlled Osteotomies

Brazilin Removes Toxic Alpha-Synuclein and Seeding Competent Assemblies from Parkinson Brain by Altering Conformational Equilibrium

C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY

O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

The Infectious Diseases Physician in the Future of Healthcare: Not Only About Antibiotic Prescribing

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

The Value of Infectious Diseases Specialists: Non–Patient Care Activities

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART Study

Suchergebnisse filtern